Sign In | Join Free | My
Wuhan uni-pharma bio-tech co.,ltd
Wuhan Uni-pharma Bio-tech Co.,Ltd
Home > Infusion Medicine >

Mannitol Injection Medical Drug Infusion USP IV Use Nonelectrolyte Obligatory Osmotic Diuretics

Wuhan uni-pharma bio-tech co.,ltd
Wuhan uni-pharma bio-tech co.,ltd
Province/State: Hubei
Country/Region: China
Tel: 86-27-82316816

Mannitol Injection Medical Drug Infusion USP IV Use Nonelectrolyte Obligatory Osmotic Diuretics

Brand Name : unipharma
Model Number : 20g/100 mL & 50g/250ml
Certification : GMP,ISO9001
Place of Origin : CHINA
MOQ : 50000 bottles
Price : USD0.14-USD0.23
Payment Terms : L/C, D/A, D/P, T/T, Western Union, MoneyGram
Supply Ability : 500,000 bottles
Delivery Time : 40 days
Packaging Details : 25 bottles/carton or according to customer requirement
Generic Name : Mannitol Injection, USP
Specification : 20g/100 mL & 50g/250ml
Class : diuretic
Route of administration : for intravenous administration
pH: (4.5–7.0) : 5.3
Molecular Weight : 182.17
Shelf life : 2 years
Contact Now
Mannitol injection USP (20g/100 mL & 50g/250ml) IV use PP/glass bottle/bag nonelectrolyte, obligatory, osmotic diuretics
Mannitol Injection USP is a sterile, nonpyrogenic solution of Mannitol USP in a single dose container for intravenous administration. It contains no antimicrobial agents. Mannitol is a 6-carbon sugar alcohol prepared commercially by the reduction of dextrose. Although virtually inert metabolically in humans, it occurs naturally in fruits and vegetables. Mannitol is an obligatory osmotic diuretic.

Each 100 mL contains:

Mannitol USP 20 g; Water for Injection USP qs

Molecular Formula


Mannitol Injection USP is one of the nonelectrolyte, obligatory, osmotic diuretics. It is freely filterable at the renal glomerulus, only poorly reabsorbed by the renal tubule, not secreted by the tubule, and is pharmacologically inert.

Mannitol, when administered intravenously, exerts its osmotic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Only relatively small amounts of the dose administered is metabolized. Mannitol is readily diffused through the glomerulus of the kidney over a wide range of normal and impaired kidney function. In this fashion, approximately 80% of a 100 gram dose of mannitol will appear in the urine in three hours with lesser amounts thereafter. Even at peak concentrations, mannitol will exhibit less than 10% of tubular reabsorption and is not secreted by tubular cells. Mannitol will hinder tubular reabsorption of water and enhance excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate.

This increase in extracellular osmolarity effected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial edema, and elevated intraocular pressure.


Promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.
Reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass.
Reduction of elevated intraocular pressure when the pressure cannot be lowered by other means.
Promotion of urinary excretion of toxins.


Well-established anuria due to severe renal disease.
Severe pulmonary congestion or frank pulmonary edema.
Active intracranial bleeding except during craniotomy.
Severe dehydration.
Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.
Progressive heart failure or pulmonary congestion after institution of mannitol therapy.


This solution is for intravenous use only.

The total dosage, concentration, and rate of administration should be governed by the nature and severity of the condition being treated, and the patient's fluid requirement and urinary output. The adult dosage ranges from 50 to 200 g in a 24-hour period, but in most cases an adequate response will be achieved at a usual dosage of approximately 100 g/24 hours. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 mL/hour. Lower mannitol concentrations and solutions containing sodium chloride are useful in preventing dehydration and electrolyte depletion. This outline of administration and dosage is only a general guide to therapy.

Dosage requirements for patients 12 years of age and under have not been established. As with adults, dose is dependent on weight, clinical condition, and laboratory results. Follow recommendations of appropriate pediatric reference text.

Product Tags:

infusion drugs


infusion injection

China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

Mannitol Injection Medical Drug Infusion USP IV Use Nonelectrolyte Obligatory Osmotic Diuretics Images

Inquiry Cart 0
Send your message to this supplier
Enter your email please.
To: Wuhan uni-pharma bio-tech co.,ltd
Characters Remaining: (0/3000)
Inquiry Cart 0